Wave Life Sciences

Be Bio is focused in developing engineered B cells as a new category of cellular medicines.In April 2022, Be Biopharma closed a $130 million financing, bringing the total investment to $180 million.In October 2020, Be Biopharma launched with $52 million in a series A financing to develop B cells as medicines to treat diseases with the human body’s native protein factories

invIOs, formerly known as APEIRON Cell Therapies (a spin off of APEIRON Biologics and currently a subsidiary of invIOs Holding AG), is a biotech company focused on developing immunotherapies for the potential treatment of cancer.In December 2021, the company, a wholly owned subsidiary of APEIRON Biologics, had been assigned APEIRON's cancer immunotherapy activities and all related clinical and preclinical R&D projects. The company announced that it would commence operations on 1 January 2022. In April 2022, APEIRON Biologics announced that the new structure of the group had been approved through the demerger of its preclinical and clinical development activities and the creation of a new fully separate holding company, invIOs Holding AG. The shareholders in APEIRON Biologics would be granted shares in invIOs Holding AG pro rata to their current shareholdings in APEIRON Biologics. invIOs Holding AG would manage the operations of its wholly-owned subsidiaries invIOs and APEIRON Respiratory Therapi

Wave Life Sciences Ltd.于2012年7月23日在新加坡注册成立。该公司是一家临床生物制药公司，以创新和专有合成化学药物开发平台，使用的设计，开发和商业化的先入类或最佳的类核酸治疗考生广泛的管道。核酸治疗有解决那些难以治疗与小分子药物和生物制剂的潜力，并已成为一个庞大而有前途的一类药物。公司最初开发核酸治疗剂靶向的遗传缺陷要么减少疾病促进蛋白质的表达或改造生产失调突变蛋白进入生产的功能性蛋白质。该公司的平台是由其创新和专有立体技术的推动，使之合理设计，优化和制造stereopure核酸治疗，它认为具有药物属性优于寡核苷酸的立体异构体混合物，目前市场上还是处在发展中。